Key Drivers
- Strong FCF
- High leverage
- Interest burden
AIAI Summary
Surgery Partners is best viewed not as a growth roll‑up but as a highly‑levered cash‑flow arbitrage where equity upside hinges on visible deleveraging (material debt paydown or refinancing to cut interest), disciplined redeployment/divestitures to crystallize asset value, and near‑term margin stabilization—without those concrete actions equity remains constrained and downside risk is elevated.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong FCF
- •High leverage
- •Interest burden
SGRY produces strong operating cash flow and FCF with healthy margins and positive EBITDA, but heavy leverage and large interest expense convert operating profits into a FY net loss, making the equity high-risk despite near‑term liquidity.
Price Behavior
Key Price Behavior Insights:
- •Strong downtrend
- •Below short SMA
- •Defined support
Price fell ~24% over the last month to $11.80 and trades ~14.6% below the 21-day SMA (~$13.80), signaling clear near-term downward momentum and key risk at the $11.80 support.
Rapid ~24% decline from $15.54 to $11.80 over the last month
Sentiment & News
Key News Insights:
- •Margin shortfall
- •Shareholder probes
- •Active M&A
Surgery Partners saw a sharp share drop to 52-week lows after Q4 results and cautious FY2026 guidance revealed margin shortfalls and disclosure issues, triggering shareholder probes and activist scrutiny despite continued M&A, a new board appointment, and mixed analyst sentiment.
Expect continued near-term downside pressure and volatility from confidence and disclosure concerns, though valuation and assets may attract longer-term buyer interest
Similar Companies in Healthcare
Other companies in the same sector with AI ratings